CO2022000481A2 - Inhibidores de enzimas - Google Patents
Inhibidores de enzimasInfo
- Publication number
- CO2022000481A2 CO2022000481A2 CONC2022/0000481A CO2022000481A CO2022000481A2 CO 2022000481 A2 CO2022000481 A2 CO 2022000481A2 CO 2022000481 A CO2022000481 A CO 2022000481A CO 2022000481 A2 CO2022000481 A2 CO 2022000481A2
- Authority
- CO
- Colombia
- Prior art keywords
- enzyme inhibitors
- compounds
- formula
- therapy
- compositions
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos de Fórmula (I) Fórmula ( I) composiciones que comprenden dichos compuestos; el uso de dichos compuestos en terapia; y métodos para tratar pacientes con dichos compuestos; en donde A, B y n son como se definen en el presente documento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2019/052357 WO2021032934A1 (en) | 2019-08-21 | 2019-08-21 | Enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022000481A2 true CO2022000481A2 (es) | 2022-01-28 |
Family
ID=67777357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0000481A CO2022000481A2 (es) | 2019-08-21 | 2022-01-20 | Inhibidores de enzimas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220298141A1 (es) |
EP (1) | EP4017849A1 (es) |
JP (1) | JP2022551794A (es) |
KR (1) | KR20220050944A (es) |
CN (1) | CN114286820A (es) |
AR (1) | AR118084A1 (es) |
AU (1) | AU2019462140A1 (es) |
BR (1) | BR112022001341A2 (es) |
CA (1) | CA3147566A1 (es) |
CO (1) | CO2022000481A2 (es) |
IL (1) | IL289914A (es) |
MX (1) | MX2022001004A (es) |
TW (1) | TW202115019A (es) |
WO (1) | WO2021032934A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
KR20220002890A (ko) | 2019-03-19 | 2022-01-07 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물 |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[(4-磺胺哌嗪-1-基)甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140905B1 (en) * | 1998-12-23 | 2003-05-14 | Eli Lilly And Company | Heteroaromatic amides as inhibitor of factor xa |
JP4951339B2 (ja) | 2003-08-27 | 2012-06-13 | オプソテツク・コーポレイシヨン | 眼血管新生疾患の治療のための併用療法 |
WO2005035514A2 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
US20070149547A1 (en) * | 2004-02-12 | 2007-06-28 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
PL2683397T3 (pl) | 2011-03-09 | 2018-01-31 | Csl Behring Gmbh | Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
MX2018002006A (es) * | 2015-08-20 | 2018-06-19 | Boehringer Ingelheim Int | Benzamidas apareadas novedosas. |
US10174002B2 (en) * | 2015-10-07 | 2019-01-08 | NuBridge BioSciences | Pyridine derivatives as CFTR modulators |
WO2017123518A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
CN109475530B (zh) | 2016-05-23 | 2022-03-01 | 洛克菲勒大学 | 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂 |
CN109476614A (zh) * | 2016-07-22 | 2019-03-15 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
EP3541375B1 (en) | 2016-11-18 | 2023-08-23 | Merck Sharp & Dohme LLC | Factor xiia inhibitors |
US11014920B2 (en) | 2016-11-18 | 2021-05-25 | Merck Sharp & Dohme Corp. | Factor XIIa inhibitors |
US10934276B2 (en) * | 2016-12-16 | 2021-03-02 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
CN108623537B (zh) * | 2017-05-24 | 2021-11-12 | 中南大学 | 含胺基侧链的芳香胺类乙酰胆碱酯酶抑制剂合成与用途 |
US11028058B2 (en) * | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US10597378B2 (en) * | 2017-09-08 | 2020-03-24 | National Health Research Institutes | Tetrahydroisoquinolines for use as MOR/NOP dual agonists |
US11312723B2 (en) | 2017-11-29 | 2022-04-26 | The Rockefeller University | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
-
2019
- 2019-08-21 CA CA3147566A patent/CA3147566A1/en active Pending
- 2019-08-21 JP JP2022504137A patent/JP2022551794A/ja active Pending
- 2019-08-21 MX MX2022001004A patent/MX2022001004A/es unknown
- 2019-08-21 KR KR1020227009176A patent/KR20220050944A/ko unknown
- 2019-08-21 BR BR112022001341A patent/BR112022001341A2/pt not_active Application Discontinuation
- 2019-08-21 CN CN201980099460.5A patent/CN114286820A/zh active Pending
- 2019-08-21 EP EP19759701.6A patent/EP4017849A1/en active Pending
- 2019-08-21 AU AU2019462140A patent/AU2019462140A1/en active Pending
- 2019-08-21 WO PCT/GB2019/052357 patent/WO2021032934A1/en unknown
- 2019-08-21 US US17/633,973 patent/US20220298141A1/en active Pending
-
2020
- 2020-02-13 AR ARP200100398A patent/AR118084A1/es unknown
- 2020-02-13 TW TW109104435A patent/TW202115019A/zh unknown
-
2022
- 2022-01-17 IL IL289914A patent/IL289914A/en unknown
- 2022-01-20 CO CONC2022/0000481A patent/CO2022000481A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202115019A (zh) | 2021-04-16 |
JP2022551794A (ja) | 2022-12-14 |
AU2019462140A1 (en) | 2022-02-24 |
IL289914A (en) | 2022-03-01 |
CN114286820A (zh) | 2022-04-05 |
EP4017849A1 (en) | 2022-06-29 |
US20220298141A1 (en) | 2022-09-22 |
CA3147566A1 (en) | 2021-02-25 |
BR112022001341A2 (pt) | 2022-03-22 |
AR118084A1 (es) | 2021-09-15 |
MX2022001004A (es) | 2022-02-21 |
KR20220050944A (ko) | 2022-04-25 |
WO2021032934A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022000481A2 (es) | Inhibidores de enzimas | |
ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
CO2022000422A2 (es) | Inhibidores de enzimas | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
CO2020001242A2 (es) | Dihidrooxadiazinonas | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
CO2023012342A2 (es) | Inhibidores de enzimas | |
CO2023008475A2 (es) | Inhibidores de enzimas | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
UY38472A (es) | Moduladores de la expresión de foxp3 |